Screen Reader Mode Icon

Introduction

Gender Diversity: 2022 Global survey of cooperative trial groups working in lymphoproliferative diseases.
Thank  you for participating in this important 10-minute survey for clinical trial groups. 
Women in Lymphoma (WiL) is an international alliance dedicated to supporting female lymphoma clinicians, researchers and educators and advocating for their greater leadership in the field. WiL collects data on female representation in lymphoma, and promotes proportionate/equal representation at conferences, on panels, in leadership committees, and in research.   
The Australasian Leukaemia & lymphoma Group (ALLG), the haematology cooperative trial group for Australia and New Zealand recently looked at its gender diversity. The results stimulated a number of constructive initiatives. WiL and the ALLG would like to learn more about gender diversity across the global network of cooperative trials groups. 
Aggregate results will be shared with all participants.

If you have any questions please feel free to make direct contact at  at info@allg.org.au or judith.trotman@health.nsw.gov.au or  https://womeninlymphoma.org  

Judith Trotman Past-Chair & Member, Steering Committee WiL and Delaine Smith, CEO ALLG

Question Title

* 1. Your name (optional)

Question Title

* 2. Your contact email (optional) 

Question Title

* 3. Name of the Cooperative Trial Group or Professional Society or other clinical research network in your country/area for the purpose of conducting investigator lead clinical trials

Question Title

* 4. Generally speaking, where does 'Lymphoma' fit into the structure of the group you are affiliated with? ie the groups only remit is lymphoma research, or lymphoma is subgroup with other haematology research, or lymphoma is a subgroup to other haematology and oncology research, or other model.
If it is easier to supply a corporate structure diagram please note the website where a copy of the diagram could be sourced from or feel free to send a copy direct to the email addresses detailed in the introduction.

Question Title

* 5. What is your affiliation with the group named in Q3

Question Title

* 6. Do you hold an additional office bearer role in the group named in Q3? eg Chair, President, Secretary, Treasurer

Question Title

* 7. Our aim is to learn about the number of members and the number of female investigator members.
If you do not know the actual group numbers, please complete the estimate fields.

Question Title

* 8. If lymphoproliferative diseases are a subgroup of the Group/Society named in Q3 please also complete the subgroup numbers.
If you do not know the actual numbers, please complete the estimate fields.

Question Title

* 9. We would like to learn about the most senior employee of the Group/Society named in Q3. Please indicate if the current most senior employee is female or male.
To help clarify, in this question we are seeking to understand the most senior paid employee, in some organisations this may not be the board or scientific doctor leader. 

  Female Male
Current Chief Executive Officer (or equivalent)

Question Title

* 10. We would like to learn about the Board or senior governing committee leadership, please indicate if the current Chair (or Chair equivalent) is female or male.
If the group you are affiliated with practices female and male co-chairing leadership at the Board or senior governing committee then please note that in the free text comment box.

  Female Male
Current Chair (or equivalent)

Question Title

* 11. We would like to learn about the make up of the Board or senior governing committee, please indicate number on the committee and the number of commitee members that are female.

Question Title

* 12. We would like to learn about the Scientific Committee leadership. Please indicate if the Scientific Committee leader is female or male.
If the group you are affiliated with practices female and male co-chairing leadership at the Scientific Committee then please note that in the free text comment box.

  Female Male
Current Chair

Question Title

* 13. We would like to learn about the make up of the Scientific Committee, please indicate number on the committee and the number of committee members that are female.

Question Title

* 14. We would like to learn about the Lymphoma Committee leadership. Please indicate if the Lymphoma Committee leader is female or male.
If the group you are affiliated with practices female and male co-chairing leadership at the Lymphoma Committee then please note that in the free text comment box.

  Female Male
Current Chair

Question Title

* 15. We would like to learn about the make up of the Lymphoma Committee, please indicate number on the committee and the number of committee members that are female.

Question Title

* 16. Group leads facilitating conferences,  forums etc...

  All the time (not negotiable always 50/50) In good faith attempts to all of the time Most of the time Some of the time Gender balance not a key consideration when selecting
Group includes male and female facilitators/chairs
Group includes male and female speakers
Group includes male and female panel representatives

Question Title

* 17. If the group you are affiliated with named in Q3 has promoted or helped send a Postdoctoral / postgraduate researcher abroad were they careful to respect gender balance? If yes in what way eg selection criteria process.

Question Title

* 18. Please enter here any recent (less than 3years) initiatives towards gender equity undertaken by the Group/Society named in Q3. 
Examples might include discussion of gender equity at a board or committee, developing processes, implementation of policies. 

Question Title

* 19. Group/Society named in Q3 has written policy for gender balance in the nomination processes for committee appointment

Question Title

* 20. Group/Society named in Q3 has written policies for diversity including gender balance

Question Title

* 21. The term “nonbinary” can mean different things to different people. How does the group you are affliated with describe gender?

Question Title

* 22. Data and statistics. 
If you are able to provide further data on request please complete contact details below

Question Title

* 23. Please make further comments or contributions here. 
This space can also be used to add any website addresses to reference your groups corporate structure, policies, reports, etc....

0 of 23 answered
 

T